![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
Nerves
-
Aiming to catch Alnylam, AstraZeneca & Ionis plan FDA filing for rare disease drug
The planned FDA submission follows the report from AstraZeneca and Ionis Pharmaceuticals that their partnered drug, eplontersen, met the main goals of a pivotal study in treating nerve pain caused by hereditary transthyretin-mediated amyloidosis. The data come one week after rival Alnylam Pharmaceuticals won FDA approval for its second drug for this rare disease.
-
Building a biotech without millions in the bank
After ten years leading the underdog startup AxoGen, CEO Karen Zaderej is a treasure trove of lessons for how to creatively persevere through tough financial times, from layoffs to reverse mergers to courting angel investors.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.